Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary

Speciality: Hematology

Description:

A warm welcome to all the medical professionals in this critical session on understanding the advancements in the classification and risk stratification of plasma cell dyscrasias. These are a diverse group of disorders arising from the clonal proliferation of plasma cells, ranging from the benign condition of Monoclonal Gammopathy of Undetermined Significance (MGUS) to the aggressive malignancy of Multiple Myeloma (MM). The ability to accurately classify and risk-stratify these disorders has been revolutionized by advancements in diagnostic tools and our understanding of their underlying biology.

Traditional methods of classification relied on clinical features, such as the presence of end-organ damage (the classic CRAB criteria: hyperCalcemia, Renal failure, Anemia, Bone lesions). However, modern risk stratification goes much deeper, incorporating genetic and molecular insights to predict disease progression and treatment response with greater precision. The revised International Staging System (R-ISS) for Multiple Myeloma, for instance, now integrates key cytogenetic abnormalities—such as del(17p), t(4;14), and t(14;16)—along with standard clinical markers. This has allowed for a more granular and accurate assessment of prognosis, directly influencing therapeutic decisions.

Furthermore, the focus is now on identifying high-risk individuals with precursor conditions like MGUS and smoldering multiple myeloma (SMM) who are most likely to progress to symptomatic disease. Advanced molecular and imaging techniques are being explored to identify those who may benefit from early intervention, even before the onset of overt symptoms. This proactive approach, guided by sophisticated risk stratification models, is poised to reshape the treatment paradigm from reactive management to early interception, offering a new hope for better patient outcomes.

See More Webinars @ Hidoc Webinars